{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:49:44Z","timestamp":1777078184346,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","award":["SP142"],"award-info":[{"award-number":["SP142"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","award":["SP263"],"award-info":[{"award-number":["SP263"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011234","name":"Bio-Rad Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jmoldx.2020.09.006","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T21:26:20Z","timestamp":1601587580000},"page":"1438-1452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Staining Performance of ALK and ROS1 Immunohistochemistry and Influence on Interpretation in Non\u2013Small-Cell Lung Cancer"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-8386","authenticated-orcid":false,"given":"Cleo","family":"Keppens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"von der Th\u00fcsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Pauwels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ales","family":"Ryska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"\u2019t Hart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3655-143X","authenticated-orcid":false,"given":"Ed","family":"Schuuring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Thunnissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Zwaenepoel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth M.C.","family":"Dequeker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2020.09.006_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib2","series-title":"IASLC Atlas of ALK and ROS1 Testing in Lung Cancer. International Association for the Study of Lung Cancer","author":"Tsao","year":"2016"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMc1415359","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"372","author":"Shaw","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/1759-7714.12613","article-title":"ALK-rearrangement in non-small-cell lung cancer (NSCLC)","volume":"9","author":"Du","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JTO.0000000000000115","article-title":"An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators","volume":"9","author":"Wynes","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib8","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1158\/1078-0432.CCR-16-1631","article-title":"Dichotomous ALK-IHC is a better predictor for ALK inhibition outcome than traditional ALK-FISH in advanced non-small cell lung cancer","volume":"23","author":"van der Wekken","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.lungcan.2019.09.023","article-title":"ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib","volume":"138","author":"Thunnissen","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib10","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.jtho.2016.07.012","article-title":"ALK immunohistochemistry in NSCLC: discordant staining can impact patient treatment regimen","volume":"11","author":"Ibrahim","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00428-012-1281-4","article-title":"EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations","volume":"461","author":"Thunnissen","year":"2012","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib12","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/PAS.0000000000000604","article-title":"Improving selection criteria for ALK inhibitor therapy in non-small cell lung cancer: a pooled-data analysis on diagnostic operating characteristics of immunohistochemistry","volume":"40","author":"Jiang","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib13","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.5301\/jbm.5000218","article-title":"ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis","volume":"31","author":"Pyo","year":"2016","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.lungcan.2020.06.019","article-title":"Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer","volume":"146","author":"Wang","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib15","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jtho.2019.07.005","article-title":"Assessment of a new ROS1 immunohistochemistry clone (SP384) for the identification of ROS1 rearrangements in patients with non-small cell lung carcinoma: the ROSING study","volume":"14","author":"Conde","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib16","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1097\/PAS.0b013e3182960fa7","article-title":"ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas","volume":"37","author":"Sholl","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib17","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.molonc.2014.03.008","article-title":"Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers","volume":"8","author":"O'Hurley","year":"2014","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ymeth.2014.01.018","article-title":"Antibody validation of immunohistochemistry for biomarker discovery: recommendations of a consortium of academic and pharmaceutical based histopathology researchers","volume":"70","author":"Howat","year":"2014","journal-title":"Methods"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/10520295.2015.1033462","article-title":"External quality assessment for immunohistochemistry: experiences from NordiQC","volume":"90","author":"Nielsen","year":"2015","journal-title":"Biotech Histochem"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib21","doi-asserted-by":"crossref","first-page":"e112159","DOI":"10.1371\/journal.pone.0112159","article-title":"The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization","volume":"9","author":"Tembuyser","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib22","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1097\/JTO.0000000000000307","article-title":"Multicenter ALK testing in non-small-cell lung cancer: results of a round robin test","volume":"9","author":"von Laffert","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib23","doi-asserted-by":"crossref","first-page":"20524","DOI":"10.18632\/oncotarget.24980","article-title":"EQA assessors expert group: a stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer","volume":"9","author":"Keppens","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00428-015-1829-1","article-title":"Proficiency testing in immunohistochemistry\u2014experiences from Nordic Immunohistochemical Quality Control (NordiQC)","volume":"468","author":"Vyberg","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41416-018-0204-9","article-title":"Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories","volume":"119","author":"Tack","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib26","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jtho.2017.08.002","article-title":"Recent advances in targeting ROS1 in lung cancer","volume":"12","author":"Lin","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/PAI.0000000000000126","article-title":"Predictive biomarkers and companion diagnostics: the future of immunohistochemistry: \u201cin situ proteomics,\u201d or just\u00a0a \u201cstain\u201d?","volume":"22","author":"Taylor","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib28","doi-asserted-by":"crossref","first-page":"408","DOI":"10.5858\/arpa.2017-0106-SA","article-title":"Immunohistochemistry of pulmonary biomarkers: a perspective from members of the Pulmonary Pathology Society","volume":"142","author":"Thunnissen","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jmoldx.2020.09.006_bib29","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00428-016-2000-3","article-title":"Testing for ROS1 in non-small cell lung cancer: a review with recommendations","volume":"469","author":"Bubendorf","year":"2016","journal-title":"Virchows Arch"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157820304827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157820304827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:15:06Z","timestamp":1761502506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157820304827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1525157820304827"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2020.09.006","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Staining Performance of ALK and ROS1 Immunohistochemistry and Influence on Interpretation in Non\u2013Small-Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2020.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}